40332-16-9

Basic information

• Product Name: BENZOIMIDAZOL-1-YL-ACETIC ACID
• Synonyms: TIMTEC-BB SBB010151;2-(BENZIMIDAZOLE-1-YL)-ACETIC ACID;2-(1H-BENZIMIDAZOL-1-YL)ACETIC ACID;1-(CARBOXYMETHYL) BENZIMIDAZOLE;1H-BENZIMIDAZOL-1-YLACETIC ACID;AKOS MSC-0005;BENZOIMIDAZOL-1-YL-ACETIC ACID;IFLAB-BB F0356-0370
• CAS NO: 40332-16-9
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Product Categories: BENZIMIDAZOLE;pharmacetical
• Mol File: 40332-16-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 406.3°Cat760mmHg
• Flash Point: 199.5°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 2.49E-07mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: BENZOIMIDAZOL-1-YL-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIMIDAZOL-1-YL-ACETIC ACID(40332-16-9)
• EPA Substance Registry System: BENZOIMIDAZOL-1-YL-ACETIC ACID(40332-16-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 40332-16-9(Hazardous Substances Data)

Usage

General Description

BENZOIMIDAZOL-1-YL-ACETIC ACID, also known as BIAA, is a chemical compound with potential therapeutic applications. It is a derivative of imidazole and acetic acid, and it has shown promise as a potential treatment for neurological and psychiatric disorders. BIAA has been studied for its potential anti-seizure and neuroprotective effects, and it may also have antidepressant and anxiolytic properties. Research on BIAA is ongoing, and further studies are needed to fully understand its potential uses and benefits. Overall, BIAA appears to be a promising compound with potential medical applications in the treatment of various neurological and psychiatric conditions.

InChI:InChI=1/C9H8N2O2/c12-9(13)5-11-6-10-7-3-1-2-4-8(7)11/h1-4,6H,5H2,(H,12,13)

Upstream product

• 51-17-2 benzoimidazole 
• 79-11-8 chloroacetic acid 
• 79-08-3 bromoacetic acid 
• 4414-74-8 2-(1H-benzo[d]imidazol-1-yl)acetonitrile 
• 7748-25-6 potassium chloroacetate 
• 503140-97-4 benzimidazol-1-ylacetic acid benzyl ester 
• 55175-50-3 1-(ethoxycarbonylmethyl)benzimidazole 

Downstream Products

• 1355446-05-7 2-(2-(1H-benzo[d]imidazol-1-yl)-N-(3-fluorophenyl)acetamido)-N-cyclopentyl-2-o-tolylacetamide 
• 6122-05-0 2-benzoimidazol-1-yl-N-[4-(4-chloro-phenyl)-thiazol-2-yl]-acetamide 

Relevant articles and documents

Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1

Different N-heteroaryl compounds bearing pyrimidine and benzimidazole moieties have been designed in silico using Discovery studio 2.5 software, synthesized and evaluated for their inhibitory activity as reverse transcriptase inhibitors against HIV-1 replication using laboratory adapted strains HIV-1IIIB (X4, subtype B) and HIV-1Ada5 (R5, subtype B), and the primary isolates HIV-1UG070 (X4, subtype D) and HIV-1VB59 (R5, subtype C). Cell-based assay showed that compounds were active at 1.394 μM concentrations (Selectivity Index: 1.29-38.39). The studies on structure-activity relationship clearly suggested anti-HIV activity of pyrimidine and benzimidazole derivatives and these findings were consistent with the in vitro cell-based experimental data. The results of molecular modeling and docking confirmed that all compounds assumed a butterfly-like conformation and showed H-bond, 'π-π' and 'π-+' and hydrophobic interactions within flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase, similar to known non-nucleoside reverse transcriptase inhibitors, such as nevirapine. In view of the results obtained, it can be said that the chemical skeletons of N, N′-bis-(pyridin-2-yl)-succinamide (14 and 15) and 1, 4-bis-benzoimidazol-1-yl-butane-1, 4-dione (16 and 17) may be used for developing potent inhibitors of HIV-1 replication, with suitable structure/pharmacophore modifications.

Analgesic and anti-inflammatory activity of new analogs of HC-030031: A TRPA1 channel antagonist

One of our study direction is research in the group of compounds affecting the TRPA1 ion channel (Transient receptor potential cation channel, subfamily A, member 1) which can perform an important function in pain (including neuropathic pain) and inflamma

Ramoplanin derivatives possessing antibacterial activity

Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.